Discovery of TAK-272: A Novel, Potent, and Orally Active Renin Inhibitor

ACS Medicinal Chemistry Letters

Volumn 7, Issue 10, 2016, Pages 933-938

  Imaeda, Yasuhiro ^a   Tokuhara, Hidekazu ^a   Fukase, Yoshiyuki ^a   Kanagawa, Ray ^a   Kajimoto, Yumiko ^a   Kusumoto, Keiji ^a   Kondo, Mitsuyo ^a   Snell, Gyorgy ^b   Behnke, Craig A ^b   Kuroita, Takanobu ^a  

^a TAKEDA PHARMACEUTICAL COMPANY LIMITED   (Japan)

^b Takeda San Diego Inc   (United States)

Author keywords

benzimidazole; dTg rat; hypertension; Renin inhibitor; SBDD; TAK 272

Indexed keywords

1 (4 METHOXYBUTYL) N (2 METHYLPROPYL) N [ 5 (MORPHOLIN 4 YL)CARBONYLPIPERIDIN 3 YL] 1H BENZIMIDAZOLE 2 CARBOXAMIDE HYDROCHLORIDE; ALISKIREN; BENZIMIDAZOLE DERIVATIVE; RENIN INHIBITOR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIHYPERTENSIVE ACTIVITY; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG BINDING SITE; DRUG BIOAVAILABILITY; DRUG DESIGN; DRUG EFFICACY; DRUG POTENCY; DRUG SCREENING; DRUG SYNTHESIS; IC50; IN VITRO STUDY; NONHUMAN; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; RAT; STRUCTURE ACTIVITY RELATION;

EID: 84991517842     PISSN: None     EISSN: 19485875     Source Type: Journal    
DOI: 10.1021/acsmedchemlett.6b00251     Document Type: Article

References (23)

1. MacGregor, G. A.; Markandu, N. D.; Roulston, J. E.; Jones, J. C.; Morton, J. J. Maintenance of blood pressure by the renin-angiotensin system in normal man Nature 1981, 291, 329-331 10.1038/291329a0
2. Zaman, M. A.; Oparil, S.; Calhoun, D. A. Drugs Targeting the Renin-Angiotensin-Aldosterone System Nat. Rev. Drug Discovery 2002, 1, 621-636 10.1038/nrd873
3. Roscioni, S. S.; Lambers Heerspink, H. J.; de Zeeuw, D. The effect of RAAS blockade on the progression of diabetic nephropathy Nat. Rev. Nephrol. 2014, 10, 77-87 10.1038/nrneph.2013.251
4. Haberman, A. B. Renin Inhibitors: A Novel Approach to Hypertension SPECTRUM Therapy Markets and Emerging Technologies 2006, 6, 1-16
5. Mende, C. W. Application of direct renin inhibition to chronic kidney diseases Cardiovasc. Drugs Ther. 2010, 24, 139-149 10.1007/s10557-010-6232-1
6. Tigerstedt, R.; Bergman, P. G. Niere und Kreislauf Skand. Arch. Physiol. 1898, 8, 223-271 10.1111/j.1748-1716.1898.tb00272.x
7. Webb, R. L.; Schiering, N.; Sedrani, R.; Maibaum, J. Direct renin inhibitors as a new therapy for hypertension J. Med. Chem. 2010, 53, 7490-7520 10.1021/jm901885s
8. Yokokawa, F.; Maibaum, J. Recent advances in the discovery of non-peptidic direct renin inhibitors as antihypertensives Expert Opin. Ther. Pat. 2008, 18, 581-602 10.1517/13543776.18.6.581
9. Yokokawa, F. Recent progress on the discovery of non-peptidic direct renin inhibitors for the clinical management of hypertension Expert Opin. Drug Discovery 2013, 8, 673-690 10.1517/17460441.2013.791279
10. Maibaum, J.; Stutz, S.; Göschke, R.; Rigollier, P.; Yamaguchi, Y.; Cumin, F.; Rahuel, J.; Baum, H.-P.; Cohen, N.-C.; Schnell, C. R.; Fuhrer, W.; Gruetter, M. G.; Schilling, W.; Wood, J. M. Structural modification of the P2′ position of 2,7-dialkyl-substituted 5(S)- amino-4(S)-hydroxy-8-phenyl-octanecarboxamides: the discovery of aliskiren, a potent nonpeptide human renin inhibitor active after once daily dosing in marmosets J. Med. Chem. 2007, 50, 4832-4844 10.1021/jm070316i
11. Vaidyanathan, S.; Jarugula, V.; Dieterich, H. A.; Howard, D.; Dole, W. P. Clinical pharmacokinetics and pharmacodynamics of aliskiren Clin. Pharmacokinet. 2008, 47, 515-531 10.2165/00003088-200847080-00002
12. Imaeda, Y.; Tawada, M.; Suzuki, S.; Tomimoto, M.; Kondo, M.; Tarui, N.; Sanada, T.; Kanagawa, R.; Snell, G.; Behnke, C. A.; Kubo, K.; Kuroita, T. Structure-based design of a new series of N-(piperidin-3-yl)pyrimidine-5-carboxamides as renin inhibitors. Bioorg. Med. Chem., published online September 13, 2016; DOI: 10.1016/j.bmc.2016.09.030.
13. Ostermann, N.; Ruedisser, S.; Ehrhardt, C.; Breitenstein, W.; Marzinzik, A.; Jacoby, E.; Vangrevelinghe, E.; Ottl, J.; Klumpp, M.; Hartwieg, J. C.; Cumin, F.; Hassiepen, U.; Trappe, J.; Sedrani, R.; Geisse, S.; Gerhartz, B.; Richert, P.; Francotte, E.; Wagner, T.; Krömer, M.; Kosaka, T.; Webb, R. L.; Rigel, D. F.; Maibaum, J.; Baeschlin, D. K. A novel class of oral direct renin inhibitors: highly potent 3,5-disubstituted piperidines bearing a tricyclic p3-p1 pharmacophore J. Med. Chem. 2013, 56, 2196-2206 10.1021/jm301706j
14. Ehara, T.; Irie, O.; Kosaka, T.; Kanazawa, T.; Breitenstein, W.; Grosche, P.; Ostermann, N.; Suzuki, M.; Kawakami, S.; Konishi, K.; Hitomi, Y.; Toyao, A.; Gunji, H.; Cumin, F.; Schiering, N.; Wagner, T.; Rigel, D. F.; Webb, R. L.; Maibaum, J.; Yokokawa, F. Structure-based design of substituted piperidines as a new class of highly efficacious oral direct Renin inhibitors ACS Med. Chem. Lett. 2014, 5, 787-792 10.1021/ml500137b
15. Lipinski, C. A.; Lombardo, F.; Dominy, B. W.; Feeney, P. J. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings Adv. Drug Delivery Rev. 1997, 23, 3-25 10.1016/S0169-409X(96)00423-1
16. Veber, D. F.; Johnson, S. R.; Cheng, H.-Y.; Smith, B. R.; Ward, K. W.; Kopple, K. D. Molecular properties that influence the oral bioavailability of drug candidates J. Med. Chem. 2002, 45, 2615-2623 10.1021/jm020017n
17. Dalvie, D. K.; Kalgutkar, A. S.; Khojasteh-bakht, S. C.; Obach, R. S.; O'Donnell, J. P. Biotransformation reactions of five-membered aromatic heterocyclic rings Chem. Res. Toxicol. 2002, 15, 269-299 10.1021/tx015574b
18. Baer, B. R.; Rettie, A. E.; Henne, K. R. Bioactivation of 4-ipomeanol by CYP4B1: adduct characterization and evidence for an enedial intermediate Chem. Res. Toxicol. 2005, 18, 855-864 10.1021/tx0496993
19. Mori, Y.; Ogawa, Y.; Mochizuki, A.; Nakamura, Y.; Sugita, C.; Miyazaki, S.; Tamaki, K.; Matsui, Y.; Takahashi, M.; Nagayama, T.; Nagai, Y.; Inoue, S.; Nishi, T. Design and discovery of new (3S,5R)-5-[4-(2-chlorophenyl)-2,2-dimethyl-5-oxopiperazin-1-yl]piperidine-3-carboxamides as potent renin inhibitors Bioorg. Med. Chem. Lett. 2012, 22, 7677-7682 10.1016/j.bmcl.2012.09.103
20. Lovering, F.; Bikker, J.; Humbelt, C. Escape from Flatland: Increasing Saturation as an Approach to Improving Clinical Success J. Med. Chem. 2009, 52, 6752-6756 10.1021/jm901241e
21. Reynolds, C. H.; Bembenek, S. D.; Tounge, B. A. The role of molecular size in ligand efficiency Bioorg. Med. Chem. Lett. 2007, 17, 4258-4261 10.1016/j.bmcl.2007.05.038
22. Leeson, P. D.; Springthorpe, B. The Influence of Drug-like Concepts on Decision-Making in Medicinal Chemistry Nat. Rev. Drug Discovery 2007, 6, 881-890 10.1038/nrd2445
23. 2 agonists using parallel synthesis protocols: A Lipophilic Efficiency (LipE) analysis Bioorg. Med. Chem. Lett. 2009, 19, 4406-4409 10.1016/j.bmcl.2009.05.062